123 related articles for article (PubMed ID: 19579641)
1. Early effects of intravenous administrations of lansoprazole and famotidine on intragastric pH.
Iida H; Inamori M; Akimoto K; Mawatari H; Endo H; Nozaki Y; Akiyama T; Ikeda T; Sakamoto Y; Fujita K; Yoneda K; Takahashi H; Yoneda M; Goto A; Abe Y; Kobayashi N; Kirikoshi H; Kubota K; Saito S; Nakajima A
Hepatogastroenterology; 2009; 56(90):551-4. PubMed ID: 19579641
[TBL] [Abstract][Full Text] [Related]
2. Preventive effects of lansoprazole and famotidine on gastric mucosal injury induced by low-dose aspirin in Helicobacter pylori-negative healthy volunteers.
Nishino M; Sugimoto M; Kodaira C; Yamade M; Uotani T; Shirai N; Ikuma M; Tanaka T; Sugimura H; Hishida A; Furuta T
J Clin Pharmacol; 2011 Jul; 51(7):1079-86. PubMed ID: 20663999
[TBL] [Abstract][Full Text] [Related]
3. The comparative effects of single intravenous doses of omeprazole and famotidine on intragastric pH.
Abe Y; Inamori M; Togawa J; Kikuchi T; Muramatsu K; Chiguchi G; Kawamura H; Kobayashi N; Kirikoshi H; Sakaguchi T; Takamura T; Nakajima A; Ueno N; Sekihara H
J Gastroenterol; 2004 Jan; 39(1):21-5. PubMed ID: 14767730
[TBL] [Abstract][Full Text] [Related]
4. Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status.
Furuta T; Shirai N; Sugimoto M; Nakamura A; Okudaira K; Kajimura M; Hishida A
Aliment Pharmacol Ther; 2005 Jul; 22(1):67-74. PubMed ID: 15963082
[TBL] [Abstract][Full Text] [Related]
5. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
Shimatani T; Inoue M; Kuroiwa T; Xu J; Mieno H; Nakamura M; Tazuma S
Clin Pharmacol Ther; 2006 Jan; 79(1):144-52. PubMed ID: 16413249
[TBL] [Abstract][Full Text] [Related]
6. Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status.
Sugimoto M; Furuta T; Shirai N; Ikuma M; Hishida A; Ishizaki T
Clin Pharmacol Ther; 2006 Nov; 80(5):539-48. PubMed ID: 17112810
[TBL] [Abstract][Full Text] [Related]
7. Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups.
Shirai N; Furuta T; Xiao F; Kajimura M; Hanai H; Ohashi K; Ishizaki T
Aliment Pharmacol Ther; 2002 Apr; 16(4):837-46. PubMed ID: 11929404
[TBL] [Abstract][Full Text] [Related]
8. Lansoprazole regimens that sustain intragastric pH > 6.0: an evaluation of intermittent oral and continuous intravenous infusion dosages.
Metz DC; Amer F; Hunt B; Vakily M; Kukulka MJ; Samra N
Aliment Pharmacol Ther; 2006 Apr; 23(7):985-95. PubMed ID: 16573801
[TBL] [Abstract][Full Text] [Related]
9. Effect of Helicobacter pylori status on intragastric pH during administration of lafutidine or famotidine.
Koike T; Ohara S; Sehine H; Kawamura M; Abe Y; Inomata Y; Iijima K; Imatani A; Shimosegawa T
Hepatogastroenterology; 2007 Jun; 54(76):1280-4. PubMed ID: 17629089
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effects of intravenous lansoprazole 30 mg and pantoprazole 40 mg twice daily on intragastric acidity in healthy Chinese volunteers: a randomized, open-labeled, two-way crossover study.
Zhan XB; Guo XR; Li ZS; Gong YF; Gao J; Liao Z; Li Z; Gao S; Liu P
Med Sci Monit; 2012 Feb; 18(2):CR125-130. PubMed ID: 22293876
[TBL] [Abstract][Full Text] [Related]
11. Four-day continuous gastric pH monitoring following anti-acid secretory drug administration: cross-over test to assess the early effects.
Suzuki T; Yamaguchi T; Odaka T; Kobayashi M; Seza A; Kouzu T; Yokosuka O
Aliment Pharmacol Ther; 2008 Jan; 27(1):66-71. PubMed ID: 17922801
[TBL] [Abstract][Full Text] [Related]
12. Intravenous esomeprazole 40 mg vs. intravenous lansoprazole 30 mg for controlling intragastric acidity in healthy adults.
Pisegna JR; Sostek MB; Monyak JT; Miner PB
Aliment Pharmacol Ther; 2008 Mar; 27(6):483-90. PubMed ID: 18162083
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of intravenous administration of combined acid suppressants in healthy dogs.
Tolbert MK; Odunayo A; Howell RS; Peters EE; Reed A
J Vet Intern Med; 2015; 29(2):556-60. PubMed ID: 25711717
[TBL] [Abstract][Full Text] [Related]
14. Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole.
Adachi K; Hashimoto T; Komazawa Y; Mihara T; Furuta K; Fujishiro H; Ishihara S; Amano Y; Hattori S; Kinoshita Y
Dig Liver Dis; 2005 Jul; 37(7):485-90. PubMed ID: 15975534
[TBL] [Abstract][Full Text] [Related]
15. Stronger inhibition of gastric acid secretion by lafutidine, a novel H2 receptor antagonist, than by the proton pump inhibitor lansoprazole.
Yamagishi H; Koike T; Ohara S; Horii T; Kikuchi R; Kobayashi S; Abe Y; Iijima K; Imatani A; Suzuki K; Hishinuma T; Goto J; Shimosegawa T
World J Gastroenterol; 2008 Apr; 14(15):2406-10. PubMed ID: 18416470
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the early effects of vonoprazan, lansoprazole and famotidine on intragastric pH: a three-way crossover study.
Ohkuma K; Iida H; Inoh Y; Kanoshima K; Ohkubo H; Nonaka T; Fujita K; Kusakabe A; Inamori M; Nakajima A
J Clin Biochem Nutr; 2018 Jul; 63(1):80-83. PubMed ID: 30087548
[TBL] [Abstract][Full Text] [Related]
17. Prevention of gastric mucosal injury induced by anti-platelet drugs by famotidine.
Uotani T; Sugimoto M; Nishino M; Ichikawa H; Sahara S; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Watanabe H; Miyajima H; Furuta T
J Clin Pharmacol; 2014 Aug; 54(8):858-64. PubMed ID: 24615745
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the effect of lansoprazole in suppressing acid secretion using 24-hour intragastric pH monitoring.
Takeda H; Hokari K; Asaka M
J Clin Gastroenterol; 1995; 20 Suppl 1():S7-9. PubMed ID: 7673616
[TBL] [Abstract][Full Text] [Related]
19. Prospective, randomized comparison of lansoprazole suspension, and intermittent intravenous famotidine on gastric pH and acid production in critically ill neurosurgical patients.
Brophy GM; Brackbill ML; Bidwell KL; Brophy DF
Neurocrit Care; 2010 Oct; 13(2):176-81. PubMed ID: 20596795
[TBL] [Abstract][Full Text] [Related]
20. Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers.
Wilder-Smith CH; Röhss K; Nilsson-Pieschl C; Junghard O; Nyman L
Digestion; 2003; 68(4):184-8. PubMed ID: 14691345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
